Epidemiologic Features of Inflammatory Bowel Disease in Guilan Province, North of Iran, During 2002-2012

Fariborz Mansour-Ghanaei1*, Maryam Haghkerdar2, Farahnaz Joukar3, Keyvan Aminian4, Mahmoud Yousefi Mashhour2, Afshin Shafaghi2, Saba Fakhriyeh Asl4, Zahra Ghanavi2

1. Professor, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
2. Researcher, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
3. Msn, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
4. Assistant Professor, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
5. Associate Professor, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran

ABSTRACT

BACKGROUND

The geographical incidence of IBD varies considerably. This study aimed to survey the epidemiologic features of IBD in Guilan province, North of Iran, during ten years duration.

METHODS

In this retrospective cross-sectional study, we assessed the documents of 868 patients with IBD referred to private and governmental clinics of Guilan province between 2002 and 2012. Variables such as demographic data, risk factors, diagnosis, extraintestinal manifestations and type of treatment were collected.

RESULTS

Among 868 patients with IBD, 756 patients (87.1%) diagnosed as UC and 112 patients (12.9%) as CD. The mean age of patients with UC and CD was 46.73±15.79 and 40.15±14.27 years respectively. Male/female ratio in UC and CD was 0.92:1 and 0.75:1 respectively. The most common age of disease initiation in UC was 40-59 years and in CD 20-39 years (p<0.001). Extraintestinal manifestations were seen in 25.4 percent of patients with IBD. Most of patients were treated with combination of two drugs: salicylates and azathioprine (p<0.04). The incidence of IBD gradually increased during the past 4 years in Guilan province.

CONCLUSION

This study showed that CD were presented significantly more common in younger patients than UC and totally the disease was slightly more common in female.

KEYWORDS
Epidemiology; Inflammatory Bowel Diseases (IBD); Ulcerative Colitis (UC); Crohn’s Disease (CD)

INTRODUCTION

Inflammatory Bowel Diseases (IBD) including ulcerative colitis (UC) and Crohn’s Disease (CD) are chronic inflammatory disorders of the gastrointestinal tract identified by episodes of relapse and remission. Two identified subtypes of the disease involve the gastrointestinal tract in different pattern. IBD had uncertain etiology; it imagined to
be caused by interplaying among different environmental, genetic and immunologic factors.\textsuperscript{2-4} Previous study revealed that different factors such as infectious diseases and nutrition during infancy, tonsillectomy, appendectomy, lifestyle factors and diet, domestic hygiene, refrigeration of food, time scales of socioeconomic evolution, drugs (nonsteroidal anti-inflammatory drugs [NSAIDs] and oral contraceptive pills [OCPs]), smoking, intestinal pathogens, and measles vaccination play a role in IBD.\textsuperscript{1,2} Based on geographical, racial, genetic, sexual, and habitual differences, epidemiological studies are needful.\textsuperscript{5}

Numerous studies which have been directed on the epidemiology of IBD; show considerable differences on geographical incidence.\textsuperscript{6-9} In recent decades, the incidence of IBD has been relatively stable, in areas such as U.S. and Europe which are precedent in incidence of IBD.\textsuperscript{10} It is estimated that up to 1.4 million people in the United States and 250,000 people in the United Kingdom suffer from IBD.\textsuperscript{11} However, incidence of IBD increased in previously low incidence areas such as Asia.\textsuperscript{12-14} NG et al. expressed that the crude annual overall incidence values per 100,000 individuals were 1.37 for IBD in Asia (0.76 for UC, 0.54 for CD, and 0.07 for IBD-undetermined).\textsuperscript{11} This increase most likely relates to improved physician awareness and diagnostic modalities, environmental and lifestyle factors according to socioeconomic change and rapid industrialization in Asian countries.\textsuperscript{15}

Although the prevalence and incidence of IBD have not been properly studied in Iran, our country is mentioned as a country with an increasing rate of IBD.\textsuperscript{16-18} Iran is a wide country with different ethnicities, so more studies with focus on epidemiologic and clinical features of IBD can elucidate its pattern in Iran.\textsuperscript{19} This study aimed to survey the epidemiologic features of IBD in Guilan province, North of Iran.

MATERIALS AND METHODS

In this retrospective cross sectional study, we assessed the documents of 868 patients with IBD that referred to private and governmental clinics and hospitals of Guilan province, North of Iran, during 2002 - 2012. Patients with definite diagnosis of IBD were included. The diagnosis of IBD was confirmed based on clinical manifestation, radiologic, colonoscopic and pathologic findings and opinion of a gastroenterologist. Variables such as demographic data (age, gender, place of living), risk factors (smoking, family history, age at initiation of disease, duration of disease and age at initiation of complication), and diagnosis (site of involvement, pathologic and radiologic findings), extraintestinal manifestations and type of treatment (corticosteroids, Immunosuppressive drugs, salicylates, antibiotics and anti TNF drugs) were evaluated.

Extraintestinal manifestations consist of musculoskeletal, ocular, dermatological, hepatic and pulmonary systems involvements. According to Esmat et al., our diagnosis of UC was also based on the evidence of diffuse mucosal disease of colon with different proximal extentions from the rectum, superficial inflammation, crypt abscess, cryptitis and rectal involvement without any evidence of small bowel involvement other than backwash ileitis, in the same way CD was defined as skip lesions at endoscopy, cobblestone appearance, mucosal ulceration on colonoscopy, aphthus lesion found during upper endoscopy, deep inflammation or chronic terminal ileal inflammation with or without radiologic evidence of skip lesions, structuring disease, fistulizing disease existence of perianal disease (skin tags, abscess, fistula),\textsuperscript{20} or small intestinal involvement and noncaseating granulomas. Indeterminate colitis (IC) was defined as an active and patchy architectural distortion, in the absence of small bowel involvement after radiologic evaluation, ileal intubations, an inconclusive endoscopic appearance, and histologic features that were not specifically diagnostic for CD or UC.\textsuperscript{2,3}

All the information was collected for each case and then statistical analysis of quantitative and qualitative data was conducted using SPSS software (version 18, USA) by chi square test. Frequency distributions of data were reported as mean ± SD.

Ethical Considerations:

This study was approved by ethics committee of
RESULTS

Table 1 shows the demographic and clinical profile of the total number of patients with IBD. 756 people (87.1%) had UC and 112 of them (12.9%) had CD. The mean age of patients with UC and CD was 46.73±15.79 and 40.15±14.27 years respectively. The most common age of disease in UC was 40-59 years and in CD was 20-39 years. Patients with CD were significantly younger than patients with UC \( (p<0.001) \). Male/female ratio in UC and CD was 0.92:1 and 0.75:1 respectively. This ratio was not significantly different between two diseases \( (p=0.62) \). In this study 12.6% of patients with UC and 12.5% in CD had a family history of IBD. 3.3% and 4.5% smoked Cigarette in patients with UC and CD respectively. Frequency of positive family history and cigarette smoking was not different between two disease groups \( (p=0.9 \) and \( p=0.7) \). The mean age at initiation of disease in patients with UC and CD was 40 and 34.5 years respectively. The most common age of disease initiation in UC was 40-49 years and in CD 20-29 years that was significantly different \( (p<0.001) \). The mean duration of disease was 4 and 5 years in UC and CD respectively. Most of patients suffered from disease less than five years in UC and CD. Duration of disease was significantly different \( (p<0.005) \). The mean age at initiation of complication was 40 years in UC and 32 years in CD. Complications significantly initiated earlier in patients with CD \( (p<0.001) \). In most of patients, complication was initiated at 30-39 years in UC (28%) and 20-29 years in CD (23.6%). In present study, 25.4 percent of patients with IBD suffered from extraintestinal manifestations of IBD (191 patients in UC and 30 patients in CD) (Table 1).

The frequency of arthritis, as the most prevalent extraintestinal manifestation was 36 percent.

Most of patients were treated with combination of two drugs (60% in UC and 72.3% in CD). The most common combination therapy was Salicylates and Azathioprine. Then Salicylates were the most common drugs in both groups (38.4% in UC and 25.9% in CD). Treatment in two groups was significantly different \( (p=0.04) \) (Table 2). The incidence of IBD showed in Figure 1.

DISCUSSION

In the recent decades, the incidence of UC in western countries gradually increased and a few years later, a similar increase was occurred in CD. Studies in developing countries indicated that although, in comparison with Europe and North America, IBD still has a low incidence and prevalence in Asian countries, it is increasing rapidly. Previous studies in Iran revealed an increasing rate of UC and CD. In this study we assessed the epidemiological features of 868 patients with IBD in a clinic and hospital based study in Guilan Province during 10 past years.

Our study showed that CD was presented significantly more common in younger patients than UC. It is in agreement with previous studies. The mean age of patients with UC and CD was 46.73 and 40.15 years respectively in our study. It was higher than similar studies. Taghavi et al. showed 34.68 years for UC and 32.97 years for CD. In this study we assessed the epidemiological features of 868 patients with IBD in a clinic and hospital based study in Guilan Province during 10 past years.

The ratio of Male to female in this study is different with other studies (0.92:1 in UC and 0.75:1 in CD). In a report by Shirazi et al.\(^1\),\(^9\) it was 1.08:1 in UC and 1.83:1 in CD. Just the same as Taghavi et al.\(^1\) reported male/female ratio was 0.9:1 and 0.98:1 for UC and CD patients, respectively. In other studies conducted by Aghazadeh et al.\(^2\) and vahedi et al.\(^2\) in Iran, the male/female ratio was reported to be 0.8:1 and 0.7:1 for UC, also Fallahi et al.\(^2\) and Derakhshan et al.\(^2\) stated 1.4:1 and 1.2:1 for CD patients, in series. A review study in Asia by Prideaux showed an equal gender distribution for UC and demonstrating male predominance for CD.\(^1\)

In Asia, positive family history was reported in 0.0-3.4% of patients with IBD that is lower than the 10-25% in Western countries. In similar studies conducted by Thia et al. & Park et al. in Singapore and South Korea, IBD was reported in 0.3% of patients, family.\(^1\)
Table 1: Demographic and clinical profile of patients with IBD

| Variables                  | UC  | CD  | \( p \) value |
|----------------------------|-----|-----|---------------|
|                            | Frequency | Percentage | Frequency | Percentage |
| **Age**                    |       |       |               |            |
| <20                        | 26   | 3.5  | 9            | 8.1        |
| 20-39                      | 252  | 33.3 | 55           | 49.1       |
| 40-59                      | 329  | 43.5 | 37           | 33         |
| 60-79                      | 130  | 17.2 | 11           | 9.8        |
| >80                        | 19   | 2.5  | 0            | 0          |
| **Gender**                 |       |       |               |            |
| Male                       | 362  | 47.9 | 48           | 42.9       |
| Female                     | 394  | 52.1 | 64           | 57.1       |
| **Family history**         |       |       |               |            |
| Yes                        | 95   | 12.6 | 14           | 12.5       |
| No                         | 661  | 87.4 | 98           | 87.5       |
| **Smoking**                |       |       |               |            |
| Yes                        | 25   | 3.3  | 5            | 4.5        |
| History of previous smoking| 32   | 4.2  | 4            | 3.6        |
| No                         | 669  | 88.5 | 103          | 91.9       |
| **Age at initiation of disease** |       |       |               |            |
| <20                        | 48   | 6.3  | 16           | 14.3       |
| 20-29                      | 109  | 14.4 | 26           | 23.2       |
| 30-39                      | 139  | 18.4 | 23           | 20.5       |
| 40-49                      | 179  | 23.7 | 21           | 18.7       |
| 50-59                      | 144  | 19.1 | 17           | 15.2       |
| >60                        | 137  | 18.1 | 9            | 8.1        |
| **Duration of disease**    |       |       |               |            |
| <5                         | 493  | 65.2 | 57           | 50.9       |
| 5-9                        | 202  | 26.8 | 38           | 33.9       |
| 10-14                      | 39   | 5.6  | 14           | 12.5       |
| 15-19                      | 17   | 2.2  | 2            | 0.8        |
| 20-24                      | 4    | 0.1  | 0            | 0          |
| >25                        | 1    | 0.1  | 1            | 0.9        |
| **Age at initiation of complication** |       |       |               |            |
| <20                        | 25   | 5.5  | 15           | 19.7       |
| 20-29                      | 64   | 14   | 18           | 23.6       |
| 30-39                      | 128  | 28   | 17           | 22.4       |
| 40-49                      | 98   | 21.4 | 17           | 22.4       |
| 50-59                      | 77   | 16.9 | 5            | 6.6        |
| >60                        | 65   | 14.2 | 4            | 5.3        |
| **Extraintestinal manifestations** |       |       |               |            |
| Yes                        | 191  | 25.3 | 30           | 26.5       |
| No                         | 565  | 74.7 | 82           | 73.5       |

Table 2: The frequency of drugs that administrated for treatment of patients with IBD

| Treatment                        | UC  | CD  | \( p \) value |
|----------------------------------|-----|-----|---------------|
|                                 | Frequency | Percentage | Frequency | Percentage |
| Prednisolone                     | 3   | 0.4 | 0             | 0          |
| Immunosuppression drugs          | 5   | 0.7 | 0             | 0          |
| Salicylates                      | 290 | 38.4| 29           | 25.9       |
| Antibiotics                      | 3   | 0.4 | 2             | 1.8        |
| Anti TNF drugs                   | 1   | 0.1 | 0             | 0          |
| Combination of 2 drugs (Salicylates and Azathioprine) | 454 | 60 | 81           | 72.3       |
Aghazadeh et al. and Shirazi et al. reported lower positive family history in their population.\textsuperscript{19,23} in our study, the rate of positive family history were higher than previous studies. Our study showed that 12.6\% of patients with UC and 12.5\% in CD had a family history of IBD. Therefore, when a patient has lower GI symptom and family history of IBD, this disease should be considered for screening.

Smoking is one of the most consistently environmental influences on IBD. Studies in the West have shown that smoking is a risk factor for the development of CD but is protective for the development of UC.\textsuperscript{12} Taghavi et al. revealed that frequency of smoking was 5.2\% in UC and 7.4\% in CD.\textsuperscript{17} In our study, 3.3\% and 4.5\% smoked Cigarette in patients with UC and CD respectively that is lower than previous studies.

In previous studies, the prevalence of extraintestinal manifestations in IBD is approximately 25–40\%.\textsuperscript{28-30} In our study, the prevalence of extraintestinal manifestations of IBD was 25.4\%.

In a report by Jiang and colleagues, 90.5\% of patients were prescribed 5-ASA, whereas approximately 33.0\% took steroids and 27.5\% were prescribed immunosuppressors.\textsuperscript{31} Shirazi et al. reported the majority of patients with CD (41.2\%) and UC (76\%) were treated with only 5-amino salicylic acid (5-ASA).\textsuperscript{19} our study showed that most of patients were treated with combination of two drugs: Salicylates and azathioprine (60\% in UC and 72.3\% in CD). Then Salicylates were the most common drugs in both groups (38.4\% in UC and 25.9\% in CD). This difference can be related to severity of disease in patients that we did not consider it in our study.

This study showed that the incidence of IBD gradually increased during the past 4 years. Taghavi et al. also showed an obvious increase in the new cases of IBD in the past three decades. This development can be associated with augmentation of the diagnostic services and/or increase in public information, although; it is still not obvious whether this increase in Iran is attributable to the environmental features emanating from industrialization or other unfamiliar factors.\textsuperscript{17}

As a limitation, our study was not a population based study. Also we did not assess the complication details and severity of disease. Lag time between initiations and diagnosis also did not assess in this study. So it is suggested to do population based prospective studies with considering all related factors and details of disease in future.

This study showed that CD were presented significantly more common in younger patients than UC and totally the disease was slightly more common in female. In addition, family history was more frequent in this study. It is suggested to plan more educational program to improve the time of diagnosis.

ACKNOWLEDGMENT

This study was supported by the Gastrointestinal and Liver Diseases Research Center (GLDRC) of Guilan University of Medical Sciences (GUMS). This survey was approved by ethical committee of GLDRC. This study is a part of an Internist thesis. We would like to thank all members of Gastrointestinal and Liver Diseases Research Center (GLDRC) that assisted us in this study.

Sources of funding: This study was initiated and conducted by Gastrointestinal and Liver Diseases Research Center (GLDRC) of Guilan University of Medical Sciences (GUMS).

CONFLICT OF INTEREST

The authors declare no conflict of interest related to this work.

REFERENCES

1. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. \textit{Clin Epidemiol} 2013;5:237-47.
Features of IBD in Guilan Province, North of Iran

2. Vahedi H, Merat S, Momtahan Sh, Olfati G, Kazzazi AS, Tabrizian T, et al. Epidemiologic Characteristics of 500 Patients with Inflammatory Bowel Disease in Iran Studied from 2004 through 2007. *Arch Iran Med* 2009;12:454-60.

3. Pinsk V, Lemberg DA, Grewal K, Barker CC, Schreiber RA, Jacobson K. Inflammatory bowel disease in the South Asian Pediatric Population of British Columbia. *Am J Gastroenterol* 2007;102:1077-83.

4. Jussila A, Virta LJ, Kautiainen H, Rekimo R, Nieminen U, Färkkilä MA. Increasing Incidence of Inflammatory Bowel Diseases between 2000 and 2007: A Nationwide Register Study in Finland. *Inflamm Bowel Dis* 2012;18:555-61.

5. Safarpour AR, Hosseini SV, Mehrabani D. Epidemiology of Inflammatory Bowel Diseases in Iran and Asia; a Mini Review. *Iran J Med Sci* 2013;38:140-9.

6. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down? *World J Gastroenterol* 2006;12:6102-8.

7. Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? *Eur J Intern Med* 2000;11:191-6.

8. Delco F, Sonnenberg A. Commonalities in the time trends of Crohn’s disease and ulcerative colitis. *Am J Gastroenterol* 1999;94:2171-6.

9. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. *Eur J Gastroenterol Hepatol* 2003;15:1275-80.

10. Ye L, Cao Q, Cheng J. Review of inflammatory bowel disease in China. *Scientific World Journal* 2013;2013:296470.

11. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn’s and Colitis Epidemiology Study. *Gastroenterology* 2013;145:158-65.

12. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: A systematic review. *J Gastroenterol Hepatol* 2012;27:1286-80.

13. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. *Am J Gastroenterol* 2008;103:3167-82.

14. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. *Am J Gastroenterol* 2009;104:2100-9.

15. De Silva HJ, De Silva NR, De Silva AP, Jewell DP. Emergence of inflammatory bowel disease ‘beyond the West’: do prosperity and improved hygiene have a role? *Trans R Soc Trop Med Hyg* 2008;102:857-60.

16. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 2011;140:1785–94.

17. Taghavi SA, Safarpour AR, Hoseini SV, Noroozi H, Safarpour M, Rahimikazerooni S. Epidemiology of Inflammatory Bowel Diseases (IBD) in Iran: A review of 740 patients in Fars province, Southern Iran. Annals of colorectal research journal. *Ann Colorectal Res* 2013;1:17-22.

18. Masoodi M, Agah S, Faghhi Kashani AH, Eghbali H. Estimation of Ulcerative Colitis Incidence in Hormozgan Province, Southern Iran. *Govareh* 2012;16:265-9.

19. Shirazi KM, Somi MH, Bafandeh Y, Saremi F, Mylanchy N, Rezaeifar P, et al. Epidemiological and Clinical Characteristics of Inflammatory Bowel Disease in Patients from Northwestern Iran. *Middle East J Dig Dis* 2013;5:86-92.

20. Esmat S, El Nady M, Elshefie Y, Naga M. Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt. *World J Gastroenterol* 2014;20:814-21.

21. Makharia GK. Rising incidence and prevalence of Crohn’s disease in Asia: Is it apparent or real? *J Gastroenterol Hepatol* 2006;21:1009–15.

22. Malekzadeh R, Varshosaz J, Merat S. Crohn’s disease: a review of 140 cases from Iran. *Ir J Med Sci* 2000;25:138-43.

23. Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firozui F. Inflammatory bowel disease in Iran: a review of 457 cases. *J Gastroenterol Hepatol* 2005;20:1691-5.

24. Fallahi GH, Moazzami K, Tabatabaeian M, Zamani MM, Asgar-Shirazi M, Najafi M, et al. Clinical characteristics of Iranian pediatric patients with inflammatory bowel disease. *Acta Gastroenterol Belg* 2009;72:230-4.

25. Derakhshan F, Naderi N, Farnood A, Firozui F, Habibi M, Rezvany MR, et al. Frequency of three common mutations of CARD15/NOD2 gene in Iranian IBD patients. *Indian J Gastroenterol* 2008;27:8-11.

26. Thia KT, Luman W, Jin OC. Crohn’s disease runs a more aggressive course in young Asian patients. *Inflamm Bowel Dis* 2006;12:57-61.

27. Park JB, Yang SK, Byeon JS, Park ER, Moon G, Myung SJ, et al. Familial occurrence of inflammatory bowel disease in Korea. *Inflamm Bowel Dis* 2006;12:1146-51.

28. Orchard T. Extraintestinal complications of inflammatory bowel disease. *Curr Gastroenterol Rep* 2003;5:512-7.

29. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. *Am J Gastroenterol* 2001;96:1116-22.

30. Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. *World J Gastroenterol* 2003;9:2300-7.

31. Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, et al. Retro-spective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. *Inflamm Bowel Dis* 2006;12:212-7.